Although Dr. Jordan commonly uses both treatment regimens at Cedars-Sinai Medical Center, only the IVIG treatment is considered to be standard of care for highly HLA-sensitized patients. The investigational component of this study is the addition of the Rituxan and currently the study has been ammended to a safety and efficacy study focusing on decreasing HLA antibodies pre-transplant and minimizing DSA post transplant.